24/02/2026
Great news for Australian children and adults - Australia’s first needle-free option to treat severe allergic reactions is hoped to provide more choice for people at risk of life-threatening anaphylaxis.
The Therapeutic Goods Administration (TGA) recently approved the neffy adrenaline (epinephrine) 2 mg nasal spray vial for the treatment of anaphylaxis in adults and children aged four years and over and weighing 15 kg and over.
A new adrenaline-based nasal spray represents ‘the biggest change in the anaphylaxis space’ in more than two decades.